AgomAb Therapeutics NV (NASDAQ:AGMB) Given Average Recommendation of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.75.

Separately, HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company.

AgomAb Therapeutics Stock Down 2.5%

Shares of AGMB opened at $12.32 on Friday. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82. The business has a 50-day moving average price of $11.72.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.